LAUSR

1. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360–74. 2. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009;60:2193–200. 3. Venalis P, Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford) 2014;53:397–405. 4. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990;144:1737–43. 5. Mun J, Kim YH, Yu J, Bae J, Noh DY, Yu MH, et al. A proteomic approach based on multiple parallel separation for the unambiguous identification of an antibody cognate antigen. Electrophoresis 2010;31:3428–36. 6. Park MC, Kang T, Jin D, Han JM, Kim SB, Park YJ, et al. Secreted human glycyl-tRNA synthetase implicated in defense against ERKactivated tumorigenesis. Proc Natl Acad Sci U S A 2012;109:E640–7. 7. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010;11:889–96. 8. Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford) 2014;53:2196–203.